ANIX Stock — Anixa Biosciences Inc.: Cash, EV, Pipeline

Share price

$2.77

Market cap

$96.3M

Cash

$13.7M

Enterprise value

$82.6M

Balance sheet

Cash	$13.7M
Debt	$0.0M
Net cash	$13.7M
Enterprise value	$82.6M
Basic shares	34.6M shares
Fully diluted shares	49.2M shares
Fully diluted market cap	$136.3M
Cash per share	$0.40

Cash figures as of 2026-04-30. Database snapshot: 2026-09-21.

Price history

Loading ANIX daily closes…

Loading price history…

Pipeline assets

Breast cancer vaccine

Phase 1 · Active Modality: cancer vaccine

Target alpha-lactalbumin

Partnerships Cleveland Clinic: license to breast cancer vaccine technology; U.S. Department of Defense grant funded the Phase 1 trial

Indications

triple-negative breast cancer (early-stage) (Phase 1)
prophylactic vaccination (BRCA1/2, PALB2) (Phase 1)

Status note Phase 1 completed (35 participants across three cohorts); final data presented at SABCS December 2025. Preparing Phase 2 neo-adjuvant trial pending manufacture of clinical materials; no Phase 2 start date stated.

Ovarian cancer vaccine

Stage not disclosed · Active Modality: cancer vaccine

Target AMHR2-ED (anti-Mullerian hormone receptor 2 extracellular domain)

Partnerships Cleveland Clinic: license to ovarian cancer vaccine technology

Indications

ovarian cancer (Stage not disclosed)

Status note Filing states vaccine targeting AMHR2-ED could prevent occurrence of ovarian cancer; no trial stage stated.

Lira-cel

Phase 1 · Active Modality: CAR-T cell therapy

Aliases liraltagene autoleucel

Target FSHR (FSH receptor)

Partnerships Wistar: license to chimeric endocrine receptor CAR-T technology (via subsidiary Certainty Therapeutics); H. Lee Moffitt Cancer Center: Phase 1 trial collaboration

Indications

ovarian cancer (recurrent epithelial) (Phase 1)

Status note Novel chimeric endocrine receptor-T cell therapy; Phase 1 at Moffitt began August 2022 in highly pre-treated recurrent/resistant ovarian cancer patients. Also listed: a vaccine discovery program (no distinct candidate).

Per-asset detail extracted from the 10-Q filed 2026-09-09. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05316129	Phase 1	Recruiting	Collaborator	H. Lee Moffitt Cancer Center and Research Institute	—	Ovarian Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for H. Lee Moffitt Cancer Center and Research Institute on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ANIX — Anixa Biosciences Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials